Turkish Journal of Medical Sciences最新文献

{"title":"Rare STAT3 haplotypes cause a predisposition to developing congenital anomalies of the kidney and urinary tract disorder.","authors":"Mert Polat, Feride İffet Şahin, Esra Baskin, Uğur Toprak, Kaan Savaş Gülleroğlu, Mehmet Haberal, Yunus Kasım Terzi","doi":"10.55730/1300-0144.5911","DOIUrl":"10.55730/1300-0144.5911","url":null,"abstract":"<p><strong>Background/aim: </strong>Congenital anomalies of the kidney and urinary tract (CAKUT) are characterized by renal developmental disorders in the embryonic period. STAT3 is a member of the STAT protein family. The members of this protein family play roles in various cellular mechanisms, such as the early stages of embryonic development, kidney development, and renal diseases. This study aims to determine the frequency of STAT3 rs1053004, rs744166, rs3816769, and rs4796793 polymorphisms in individuals with CAKUT.</p><p><strong>Materials and methods: </strong>Two of four polymorphisms, rs744166 (c.-1-13666T>C, NM_001369512.1) and rs4796793 ( c.-1915C>G, NM_001369512.1), were analyzed by a polymerase chain reaction (PCR) and the restriction fragment length polymorphism method. Two other polymorphisms, rs1053004 (c.*1671C>T, NM_001369512.1) and rs3816769 (c.273+314A>G, NM_001369512.1), were analyzed using real-time PCR-melting curve analysis.</p><p><strong>Results: </strong>Our research indicates that individuals with the TT allele for rs1053004 single nucleotide polymorphism have a 1.23 times greater disease risk than those with the CC allele. Those with the CC allele for rs3816769 have a 1.41 times greater risk of disease than those with the TT allele. These findings suggest a potential genetic predisposition to CAKUT. Furthermore, the research identified significant connections between rare haplotypes and CAKUT (p = 0.041). The CCTC haplotype for rs744166, rs4796793, rs1053004, and rs3816769 polymorphism was exclusively present in the CAKUT group, while the CGTT haplotype for the same polymorphisms was only detected in the control group.</p><p><strong>Conclusion: </strong>The presence of rare haplotypes for the rs1053004, rs3816769, rs4796793, and rs744166 polymorphisms may significantly affect the onset or prevention of CAKUT. These findings could potentially have important clinical implications, providing a deeper understanding of the genetic basis of CAKUT and potentially influencing future diagnostic and treatment strategies.</p>","PeriodicalId":23361,"journal":{"name":"Turkish Journal of Medical Sciences","volume":"54 6","pages":"1286-1294"},"PeriodicalIF":1.2,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11673622/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142902858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of nonmotor symptoms in myasthenia gravis patients.","authors":"Aysel Tekeşin, Çağla Şişman, Ufuk Emre Toprak, Alena Sar, Burcu Akalin, Goncagül Koşargelir, Melih Tütüncü, Enes Yiğit","doi":"10.55730/1300-0144.5951","DOIUrl":"10.55730/1300-0144.5951","url":null,"abstract":"<p><strong>Background/aim: </strong>Myasthenia gravis (MG) is chronic autoimmune disorder characterized primarily by muscle weakness and fatigue, due to autoantibodies targeting acetylcholine receptor at neuromuscular junction. Herein, it was aimed to evaluate nonmotor symptoms in MG patients and compare them with disease duration, severity, and clinical features.</p><p><strong>Materials and methods: </strong>This prospective study was conducted with two groups: 35 MG patients and 35 healthy volunteers. The patient group comprised 17 females and 18 males with a mean age of 52.9 ± 13.6 years. The control group comprised 23 females and 12 males with a mean age of 46.9 ± 12.2 years. The Myasthenia Gravis Foundation of America clinical classification and Myasthenia Gravis Composite and Turkish version of the Myasthenia Gravis Quality of Life 15 scales were applied to the patient group. To assess nonmotor functions, questionnaires evaluating the symptoms of headache, pain, depression, anxiety, sleep, physical activity, cognition, smell, and taste were applied to both the patient and control groups.</p><p><strong>Results: </strong>The results revealed prevalent and diverse nonmotor symptoms in the MG group. The Montreal Cognitive Assessment (MoCA) score and degree of olfactory function in cinnamon was statistically significantly (p < 0.05) lower in the patient group than in the control group. The degree of impairment on the MoCA, headache rate, Beck depression score, depression rate, Beck anxiety score, anxiety rate, Pittsburgh Sleep Quality Index (PSQI) score, and poor sleep quality rate were significantly higher (p < 0.05) in the patient group than in the control group.</p><p><strong>Conclusion: </strong>In conclusion, this study emphasizes the importance of recognizing and managing nonmotor symptoms in MG patients, advocating for a multidisciplinary approach to care that addresses both motor and nonmotor manifestations. By expanding our understanding of the systemic impact of MG and exploring new treatment modalities, we can improve the lives of those living with this complex autoimmune disorder. Further research is needed to elucidate the pathogenic mechanisms underlying these nonmotor manifestations, which will be pivotal in developing more targeted and effective therapeutic strategies.</p>","PeriodicalId":23361,"journal":{"name":"Turkish Journal of Medical Sciences","volume":"55 1","pages":"127-139"},"PeriodicalIF":1.2,"publicationDate":"2024-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11913501/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143658194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel nonmagnetic abutment designs for facial prostheses: an experimental study.","authors":"İrem Sözen Yanik, Ufuk Adali, Jamila Yassine, Franziska Schmidt, Wolfgang Hannak, Bahadır Ersu","doi":"10.55730/1300-0144.5953","DOIUrl":"10.55730/1300-0144.5953","url":null,"abstract":"<p><strong>Background/aim: </strong>This in vitro study was undertaken with the aim of evaluating and comparing the retentive forces of novel nonmagnetic abutment designs developed as alternatives to conventional magnetic abutments for facial prostheses.</p><p><strong>Materials and methods: </strong>A plexiglass model was constructed and two extraoral implants were placed in these blocks in a parallel position. Nonmagnetic abutments made of titanium were fabricated and screwed onto the implants. The nonmagnetic systems represent a novel design and include two different abutment designs (type 1 and type 2) with silicone attachments. Retentive force values for the three abutment types of a conventional magnetic system (CMS), the nonmagnetic abutment type 1 system (NMS1), and the nonmagnetic abutment type 2 system (NMS2) were measured at the 0th, 120th, 360th, 720th, and 1440th dislodging cycles using a test machine. Given the data's distribution characteristics, nonparametric tests were used for analysis. The Kruskal-Wallis test was used to evaluate significant differences among groups, followed by Dunn's posthoc test for specific group comparisons. The Friedman test compared the number of dislodging cycles for each group, and the Benjamini-Hochberg adjusted Wilcoxon sign-rank test was used for pairwise comparisons.</p><p><strong>Results: </strong>Both NMS1 and NMS2 exhibited significantly higher retentive forces compared to CMS for the same dislodging cycles (p < 0.01). The NMS1 group showed the highest initial retentive force (9.98 ± 0.89 N), followed by the NMS2 group (9.65 ± 0.35 N), but this difference was not statistically significant. Significant differences in retention force values were observed among the three groups across the dislodging cycles (p < 0.001). The lowest retentive force in the last dislodging cycle was observed in the CMS group (3.39 ± 0.04 N). Additionally, the retention forces decreased in all groups with each increasing dislodging cycle.</p><p><strong>Conclusion: </strong>The two newly developed nonmagnetic systems displayed higher retentive forces compared to the magnetic systems and can be considered viable alternative abutment options for facial prostheses.</p>","PeriodicalId":23361,"journal":{"name":"Turkish Journal of Medical Sciences","volume":"55 1","pages":"152-160"},"PeriodicalIF":1.2,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11913502/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143658755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reliability and validity of the Turkish version of the Infant Motor Activity Log in infants with upper extremity functional asymmetry: how often and how well?","authors":"Kübra Seyhan Biyik, Cemil Özal, Kıvanç Delioğlu, Mintaze Kerem Günel","doi":"10.55730/1300-0144.5909","DOIUrl":"10.55730/1300-0144.5909","url":null,"abstract":"<p><strong>Background/aim: </strong>Functional asymmetry in the upper extremities may occur in infants with neuromotor problems due to neurodevelopmental or musculoskeletal disorders. The aim of this study was to investigate the validity and reliability of the Turkish version of the Infant Motor Activity Log (IMAL-T), which assesses the frequency (how often) and quality (how well) of the affected arm usage during activities in infants with functional asymmetry in the upper extremities.</p><p><strong>Materials and methods: </strong>The IMAL-T was administered face-to-face to the parents of 102 infants [60 infants at high risk of developing cerebral palsy (CP) and 42 infants with brachial plexus birth injury (BPBI)], aged 6-24 months, with functional asymmetry in the upper extremities. One week later, the IMAL-T was administered again to 22 parents to determine the test-retest reliability. Cronbach's alpha and the intraclass correlation coefficient (ICC) were used to determine the internal consistency and test-retest reliability. Discriminant validity was assessed using the manual ability level (Mini Manual Ability Classification System) and the nerve injury type was evaluated using the independent samples t test. For concurrent validity, the relationship between the IMAL-T and the Pediatric Evaluation of Disability Inventory (PEDI) self-care was examined using Spearman's correlation coefficient.</p><p><strong>Results: </strong>Internal consistency (Cronbach's alpha ≥ 0.91) and test-retest reliability (ICC ≥ 0.93) of the IMAL-T were adequate. The IMAL-T scores differed according to the mini-MACS and nerve injury type (p < 0.05). Moderate to strong (CP, r ≥ 0.706, p < 0.001; BPBI, r ≥ 0.579, p < 0.001) correlation coefficients were found between the IMAL-T and PEDI self-care scores.</p><p><strong>Conclusion: </strong>The IMAL-T is a reliable and valid parent-reported outcome measure that indicates the frequency and quality of the affected arm use during age-appropriate real-life activity in infants aged 6-24 months with upper extremity functional asymmetry due to neuromotor problems. The IMAL-T can be used in early intervention to assess upper extremity functional asymmetry in Turkish infants.</p>","PeriodicalId":23361,"journal":{"name":"Turkish Journal of Medical Sciences","volume":"54 6","pages":"1271-1280"},"PeriodicalIF":1.2,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11673628/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicopathological features for the prediction of immunosuppressive treatment responses in sarcoidosis-related kidney involvement: a single-center retrospective study.","authors":"Ahmet Burak Dirim, Vafa Süleymanova, Özge Hürdoğan, Özgür Akın Oto, Ayşe Serra Artan, Savaş Öztürk, Yasemin Özlük, Işın Kiliçaslan, Halil Yazici","doi":"10.55730/1300-0144.5907","DOIUrl":"10.55730/1300-0144.5907","url":null,"abstract":"<p><strong>Background/aim: </strong>Sarcoidosis is a multisystem disorder that affects many organs, including the kidneys. This single-center retrospective study investigated the clinical, pathological, and laboratory findings of patients with kidney sarcoidosis who were treated with immunosuppressives.</p><p><strong>Materials and methods: </strong>Twenty-three patients with biopsy-confirmed kidney sarcoidosis were included. Demographic, clinical, pathological, and laboratory findings, in addition to the treatments and outcomes of 20 patients with at least one month of follow-up were evaluated.</p><p><strong>Results: </strong>The median age of the patients at the time of biopsy was 47 years (60.9% were female). The median baseline estimated glomerular filtration rate (eGFR) and proteinuria were 21.5 mL/min and 1 g/g or g/day, respectively. Nineteen of the 23 patients were diagnosed with nonglomerular disease (four had glomerular diseases). Extrarenal sarcoidosis was present in 86.7% of the patients. Granulomatous interstitial nephritis (56.5 %) and nephrosclerosis with intratubular calcific casts (17.4 %) were the two most common diagnoses. All the patients initially received 1 mg/kg/day steroids for kidney involvement. Although no statistical difference was observed in kidney function during the follow-up, steroids improved the eGFR in the first month compared with baseline in patients with nonglomerular diseases (p = 0.049). Eventually, 45% of the patients developed end-stage kidney disease, and 45% of cohort had a treatment response. Patients with higher baseline calcium levels (p = 0.03) and lower degrees of interstitial fibrosis/tubular atrophy (p = 0.043) had better kidney outcomes. Moreover, none of the patients with sarcoidosis-related secondary glomerular disease had a treatment response (p = 0.043).</p><p><strong>Conclusions: </strong>Hypercalcemia and lower interstitial fibrosis and tubular atrophy rates might be associated with better outcomes in sarcoidosis-related kidney involvement under immunosuppressive treatment. Moreover, late diagnosis, irregular follow-up, and glomerular disorders could be poor prognostic factors.</p>","PeriodicalId":23361,"journal":{"name":"Turkish Journal of Medical Sciences","volume":"54 6","pages":"1252-1264"},"PeriodicalIF":1.2,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11673659/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between papillary thyroid cancer and <i>XRCC6</i> gene polymorphisms in the Turkish population.","authors":"Egemen Akgün, Fadime Mutlu Içduygu, Demet Şengül, Ebru Alp, Mehmet Alkanat, Ayşegül Çebi, Tuncer Öztürk","doi":"10.55730/1300-0144.5902","DOIUrl":"10.55730/1300-0144.5902","url":null,"abstract":"<p><strong>Background/aim: </strong>To investigate the association between the rs2267437, rs5751129 and rs132770 polymorphisms of the <i>XRCC6</i> gene, which plays a role in repairing DNA double-strand breaks, and the risk of papillary thyroid carcinoma (PTC).</p><p><strong>Materials and methods: </strong>The study included 150 patients who had been diagnosed with PTC and 204 healthy controls. Genotyping of the SNPs was performed using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).</p><p><strong>Results: </strong>In the rs2267437 polymorphism, individuals with the GG genotype had lower risk of PTC than those with the wild-type CC genotype (p = 0.037, 95% CI: 0.19-0.96, OR: 0.67). The combined genotypes CG+GG were related to a reduced risk of PTC compared to the wild-type CC genotype (p = 0.023, 95% CI: 0.40-0.94, OR: 0.61) in the recessive model (GC+GG vs. CC). In addition, a query of the genotype-tissue expression (GTEx) database showed that the rs2267437 polymorphism may alter the expression level of <i>XRCC6</i> in whole blood (p = 0.0009) but not in thyroid tissue. There were no significant associations between the rs5751129 and rs132770 polymorphisms and PTC.</p><p><strong>Conclusion: </strong>This study demonstrated that rs2267437 polymorphism may have a protective effect against PTC in the Turkish population. However, the rs5751129 and rs132770 polymorphisms were not associated with the disease.</p>","PeriodicalId":23361,"journal":{"name":"Turkish Journal of Medical Sciences","volume":"54 6","pages":"1215-1222"},"PeriodicalIF":1.2,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11673619/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of vitamin D replacement combined with Graves' disease therapy: a retrospective cohort study.","authors":"Beyza Taşkent Sezgin, Muhammed Kizilgül, Özgür Özçelik, Taner Demirci, Hayri Bostan, Ümran Gül, Bekir Uçan","doi":"10.55730/1300-0144.5946","DOIUrl":"10.55730/1300-0144.5946","url":null,"abstract":"<p><strong>Background/aim: </strong>In Graves' disease (GD), an autoimmune disease, antibodies targeting the thyroid stimulating hormone (TSH) receptor cause the production of excessive amounts of thyroid hormone. A significant association was reported between low 25-hydroxy [25(OH)] vitamin D₃ (VitD) levels and various autoimmune disorders. Therefore, this study aimed to investigate the effects of VitD deficiency and replacement therapy on laboratory and clinical parameters in GD patients.</p><p><strong>Materials and methods: </strong>Forty GD patients and 37 healthy controls were included in this study. The GD patients were divided into two groups: the nonreplacement group was administered antithyroid treatment only (n = 18), and the replacement group was administered antithyroid treatment + VitD replacement (n = 22). Clinical and laboratory data of all the participants were compared at the time of diagnosis and 3 months after treatment.</p><p><strong>Results: </strong>Baseline serum VitD levels in the GD patients were significantly lower than the baseline serum VitD levels in the control group (16.1 ± 9.9 vs. 22.2 ± 8.5 ng/mL, p < 0.005). A significant improvement was observed in the serum VitD levels in the replacement group after three months (14.6 ± 8.3 vs. 40.4 ± 17.2 ng/mL, p < 0.001). A significant increase in the serum TSH levels and a significant decrease in the serum free triiodothyronine (fT3) and free thyroxine (fT4) levels were observed in the replacement and nonreplacement groups at the end of three months. However, there was no significant effect of VitD replacement on the serum TSH, fT3, and fT4 levels. There was no difference in the serum thyroid receptor antibodies levels between the replacement and nonreplacement groups.</p><p><strong>Conclusion: </strong>Although VitD deficiency was detected in the GD patients, there was no significant accelerating effect of VitD replacement on the thyroid hormone levels. These results need to be confirmed with studies that have larger patient numbers and longer follow-up periods.</p>","PeriodicalId":23361,"journal":{"name":"Turkish Journal of Medical Sciences","volume":"55 1","pages":"87-95"},"PeriodicalIF":1.2,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11913514/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143658019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Are there differences in the clinical and laboratory features of patients with seronegative primary Sjögren's syndrome?","authors":"Müçteba Enes Yayla, Rahime Aksoy, Emine Uslu, Zehra Karaman, Recep Yilmaz, Ahmet Ilbay, Nilgün Göveç Giynaş, Abdulbaki Gaydan, Ahmet Usta, Yeter Mahmutoğlu, Aşkın Ateş, Murat Turgay","doi":"10.55730/1300-0144.5873","DOIUrl":"https://doi.org/10.55730/1300-0144.5873","url":null,"abstract":"<p><strong>Background/aim: </strong>The objective of this study was to demonstrate the commonalities and distinctions between patients with seronegative and seropositive primary Sjögren's syndrome (pSS).</p><p><strong>Materials and methods: </strong>The records of 399 patients with pSS seen between January 2010 and June 2023 were retrospectively examined. Patients with negative antiSSA/Ro, antiSSB/La, ANA, and RF antibodies comprised the seronegative group, while patients with at least one positive antibody were included in the seropositive group.</p><p><strong>Results: </strong>The most common clinical features between the groups were arthralgia (81.2%), arthritis (11.5%), hematological involvement (19.8%), and pulmonary involvement (11.8%). In 41 patients (10.3%), no autoantibody positivity was detected. The number of patients with at least one extraarticular involvement was statistically more frequent in the seropositive group (p = 0.011). Dry mouth was found to be more prevalent among seronegative patients (p = 0.003). While hyperimmune gammaglobulinemia exhibited a higher prevalence within the seropositive group (p = 0.004), the occurrence of reduced complement levels was at similar rates in both groups. All deaths were observed exclusively within the seropositive group (17/358, 4.7%). No difference was observed between the two groups concerning mortality (p = 0.237) and malignancies (seropositive group: 9/358, 2.5% vs. seronegative group: 3/41, 7.3%, p = 0.115). There was a statistically significant association between low C4 levels (OR = 2.99 [1.09-8.16], p = 0.045 in model 1, OR = 3.10 [1.14-8.42], p = 0.022 in model 2), and the extraarticular findings.</p><p><strong>Conclusion: </strong>While hematological, renal, pulmonary, and neurological involvements are observed with similar frequency in both seronegative and seropositive pSS patients, the presence of extraarticular manifestations was more common in seropositive patients. Additionally, there was a relationship between extraarticular involvement and low C4 levels.</p>","PeriodicalId":23361,"journal":{"name":"Turkish Journal of Medical Sciences","volume":"54 5","pages":"956-962"},"PeriodicalIF":1.2,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11518344/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142547680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coexisting growing teratoma syndrome and gliomatosis peritonei following ovarian immature teratoma: a case report and literature review.","authors":"Osman Türkmen, Serra Akar Inan, Serap Akbay, Mohammad İbrahim Halilzade, İnci Halilzade, Özlem Moraloğlu Tekin","doi":"10.55730/1300-0144.5899","DOIUrl":"10.55730/1300-0144.5899","url":null,"abstract":"<p><p>Growing teratoma syndrome (GTS) is characterized by a reduction in serum tumor markers despite the growth of a benign mature teratomatous mass following chemotherapy for germ cell tumors. Gliomatosis peritonei (GP) typically accompanies ovarian teratomas, marked by the dissemination of mature glial tissue across the peritoneum. The concurrent presence of GTS and GP after treatment for ovarian immature teratoma (IMT) is notably rare, with approximately 20 reported cases. This case involves a 25-year-old patient who underwent surgical removal of an adnexal mass, which was later diagnosed as stage IIIA grade 3 ovarian IMT with parametrial involvement. Following two cycles of bleomycin, etoposide, and cisplatin chemotherapy, imaging identified new lesions adjacent to the liver and on the pelvic peritoneum. A second fertility-sparing surgery was performed, and paraffin pathology confirmed a mature teratoma within the excised specimen. Additionally, the resected pelvic peritoneum revealed nodules of mature glial tissue consistent with GP. The coexistence of GP with GTS post-IMT surgery presents a diagnostic challenge in distinguishing between malignant and benign components, which is critical to avoid unnecessarily aggressive surgical and chemotherapeutic treatments. Recognizing such cases may enable fertility-sparing surgery for these patients.</p>","PeriodicalId":23361,"journal":{"name":"Turkish Journal of Medical Sciences","volume":"54 6","pages":"1192-1197"},"PeriodicalIF":1.2,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11673672/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the efficacy of transfer energy capacitive and resistive therapy in patients with knee osteoarthritis.","authors":"Özge Tezen, Emine Esra Bilir, Öznur Uzun, Duygu Yaniktaş, Başak Şentürk, Evren Yaşar","doi":"10.55730/1300-0144.5913","DOIUrl":"10.55730/1300-0144.5913","url":null,"abstract":"<p><strong>Background/aim: </strong>This study aimed to compare the therapeutic efficacy of conventional physical therapy (CPT) methods for knee osteoarthritis (OA) and transfer energy capacitive and resistive (TECAR) therapy, a relatively new and increasingly used treatment modality, based on patient clinical outcomes assessments.</p><p><strong>Materials and methods: </strong>Two groups of 54 patients, aged 40 to 75, were randomly assigned. CPT was given to both groups. In addition to CPT, Group 2 underwent TECAR therapy for six sessions, three times a week for two weeks. The Western Ontario and McMaster Universities Arthritis Index (WOMAC) was used to measure the disability and pain levels of each patient before and at the end of treatment and at 1 month and 3 months. Additionally, goniometric measurements of each patient's knee joint range of motion and isometric quadriceps muscle strength were taken.</p><p><strong>Results: </strong>Significant improvements were noted in the VAS, WOMAC, and isometric quadriceps strength ratings in both groups between the pre- and posttreatment follow-ups. However, there was no discernible difference between the groups.</p><p><strong>Conclusion: </strong>For the conservative treatment of OA in the knee, TECAR therapy may be a helpful therapeutic approach.</p>","PeriodicalId":23361,"journal":{"name":"Turkish Journal of Medical Sciences","volume":"54 6","pages":"1302-1309"},"PeriodicalIF":1.2,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11673620/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}